← Back to Search

Cell Therapy

Intrauterine administration of hCG-activated peripheral blood mononuclear cells for Female Infertility

N/A
Waitlist Available
Research Sponsored by Fertilys
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after 48 hours of culture
Awards & highlights

Study Summary

This trial is testing whether giving extra immune cells to people with fertility issues can help them get pregnant and carry to term.

Eligible Conditions
  • Female Infertility

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after 48 hours of culture
This trial's timeline: 3 weeks for screening, Varies for treatment, and after 48 hours of culture for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical pregnancy rate
Embryo implantation rate (biochemical pregnancy)
Secondary outcome measures
Cytokines (LIF, IL-6, IL-10, TNFα, FGF-2, VEGF, IL-8) quantification by ELISA in PBMC culture medium at Day 2
Peripheral blood mononuclear cells populations (PBMC) distribution at Day 0
Peripheral blood mononuclear cells populations distribution at Day 2

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Recurrent miscarriageExperimental Treatment1 Intervention
Group II: Recurrent implantation failuresExperimental Treatment1 Intervention
Group III: No recurrent implantation failureActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Intrauterine administration of hCG-activated peripheral blood mononuclear cells
2017
N/A
~430

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)OTHER
370 Previous Clinical Trials
129,869 Total Patients Enrolled
FertilysLead Sponsor
3 Previous Clinical Trials
675 Total Patients Enrolled

Media Library

Intrauterine administration of hCG-activated peripheral blood mononuclear cells (Cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04753736 — N/A
Female Infertility Research Study Groups: Recurrent miscarriage, Recurrent implantation failures, No recurrent implantation failure
Female Infertility Clinical Trial 2023: Intrauterine administration of hCG-activated peripheral blood mononuclear cells Highlights & Side Effects. Trial Name: NCT04753736 — N/A
Intrauterine administration of hCG-activated peripheral blood mononuclear cells (Cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04753736 — N/A
Female Infertility Patient Testimony for trial: Trial Name: NCT04753736 — N/A
~0 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top